Anantharaman Shantaraman

The paper identifies TMEM106B fibril accumulation as a shared mechanism in neurodegeneration linked to genetic variants in TMEM106B and GRN.

The paper investigates how neurodevelopmental disorder-associated variants affect mitochondrial proteins and finds convergent effects on mitochondrial translation in two high-risk CNVs.

The paper identifies RNA-binding proteins interacting with tau's repeat domain using proximity labeling, showing their enrichment in Alzheimer's and tauopathies.

The paper identifies six CSF proteomic subtypes in Alzheimer's disease, linking BBB dysfunction to reduced tau and synaptic biomarkers, particularly in African Americans and men.

This study uses multiplex proteomics to identify CSF biomarkers of clinical and neuropathological heterogeneity in Lewy body dementia.

This study identifies molecular subtypes based on cryptic exon burden in hippocampal tissue, revealing proteomic changes linked to TDP-43 pathology in LATE and Alzheimer's disease.

The paper identifies proteomic differences in cerebrospinal fluid between sporadic and familial ALS subtypes using network analysis and validates biomarkers across neurodegenerative diseases.

The paper performs large-scale proteomic analysis of Alzheimer's disease brain regions across different racial and ethnic groups, identifying AD-related protein changes and APOE4 concordance with genotype.

This paper presents a multi-omics dataset from multi-ethnic Alzheimer's disease brain donors, including transcriptome, genome, and proteome data, to improve precision medicine for underrepresented populations.

This study identifies distinct presynaptic protein networks in Lewy body dementia that differ from Alzheimer's disease using network proteomics.

The paper uses long-read RNAseq to identify new RNA isoforms in Alzheimer's disease brain tissue and demonstrates their medical relevance.

The paper shows that loss of TDP-43 function leads to the expression of de novo proteins from mis-spliced mRNA transcripts in ALS/FTD.

The paper uses heparin affinity chromatography to enrich plasma proteomes in Alzheimer's disease, identifying matrisome-associated proteins correlated with AD biomarkers.